NCT04680130

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

• Status: Enrolling By Invitation
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

The investigators aim to learn more about symptoms suggestive of a neurodegenerative process.

Detailed description

The investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. Participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. At each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an MRI, an FDG PET/CT scan, a PiB PET/CT scan, a Tau PET/CT scan and/or a C-11 ER176 PET/CT scan. All participants will be asked to provide a blood sample to allow for future genetic studies.

Conditions

• PSP
• CBD
• PCA
• LPA
• Semantic Dementia
• Semantic Aphasia
• Behavioral Variant of Frontotemporal Dementia
• FTD
• PPA
• Apraxia of Speech
• MSA - Multiple System Atrophy
• Parkinson Disease

Interventions

Type	Name	Description
DRUG	C-11 PiB	Completing PET scan looking for amyloid protein
DRUG	AV1451 Tau	Completing PET scan looking for tau protein
DRUG	C-11 ER176	Completing PET scan looking for neuroinflammation

Timeline

• Start date: 2020-11-01
• Primary completion: 2050-11-01
• Completion: 2050-11-01
• First posted: 2020-12-22
• Last updated: 2025-11-21

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study